19.0502.56% ( -0.500 )
Closed: Nov 20, 16:00:00 (EDT)Valuation
Current ValuationThe current P/E ratio is -20.11, below the reasonable range, cheaper than 87.11% of the time in the past 5 years, and the industry ranks 45/57, the industry Median -1.22.
-20.11xP/E
$19.55Stock price
$-0.97Earnings per share
-20.11xP/E
Stock price$19.55Earnings per share$-0.97
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -4.27x
- Typical range
- -14.40x–5.47x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
010203040
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
LZAGYUSLonza | -401.48x | -- | $55.27B |
RGENUSRepligen | -922.19x | 134.76% | $10.89B |
TEMUSTempus AI | -56.50x | 25.30% | $10.69B |
BRKRUSBruker | -56.69x | 639.53% | $9.48B |
TXGUS10X Genomics | -112.52x | 78.24% | $7.55B |
ADPTUSAdaptive Biotechnologies | -64.38x | 1.03% | $4.54B |
ABCLUSAbcellera Biologics | -22.88x | 22.59% | $3.39B |
ALMRUSAlamar Biosciences | -36.23x | 79.38% | $1.99B |
AZTAUSAzenta | -11.78x | 102.32% | $1.97B |
FTREUSFortrea | -28.30x | 95.76% | $1.94B |
MRVIUSMaravai LifeSciences | -28.43x | 68.89% | $1.87B |
PSNLUSPersonalis | -13.37x | 26.92% | $1.60B |
CYRXUSCryoport | -20.11x | 161.67% | $991.19M |
CTKBUSCytek Biosciences | -10.18x | 44.87% | $826.55M |
OABIUSOmniAb | -16.88x | 39.35% | $733.68M |
DNAUSGinkgo Bioworks | -2.20x | 37.06% | $552.19M |
PACBUSPacific Biosc California | -4.20x | 77.06% | $550.75M |
EVOUSEvotec SE | -2.48x | 338.09% | $515.05M |
TKNOUSAlpha Teknova | -30.76x | 9.82% | $491.27M |
NAUTUSNautilus Biotechnology | -4.72x | 3.19% | $276.40M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
